DiabetesInvestor.com

Eastgate Biotech Corporation - Trading Symbol:ETBI

The Truth About Diabetes

As little as 50 years ago, a diabetes diagnosis was a death sentence. Today, diabetes is a very manageable disease, and access to effective treatment is widespread. However, the majority of today’s available diabetes therapies have not changed (at least not significantly) in the last two decades.

Sufferers continue to have to monitor blood glucose levels by prick test, and maintain healthy levels through self-administered insulin injection.

The financial incentive for developing an alternative to these cumbersome treatment regimens is huge, and this potential has not gone unnoticed.

Many companies have dedicated themselves to developing alternative assets, but none have really succeeded in altering standard of care. At least, not yet.

Eastgate Biotech Corp, (OTC:ETBI) Is set To Explode!

With an insulin mouth rinse that avoids the costs and hazards of injectables, it’s not hard to imagine a $100 million dollar market cap for this company which equates to $.10 a share.

Eastgate Biotech Corp (OTC:ETBI)

Huge Alert. Insulin Mouthwash!
Put on Your Watchlist NOW!

Subscribe To Our Newsletter

Subscribe now and don't miss out on this BREAKTHROUGH stock!

Trade With Confidence Thanks To Experienced Management Team!

Anna Gluskin (Chief Executive Officer) has over 30 years’ experience in discovering and developing opportunities in the area of biotechnology pharmaceutical and consumer health products. She has served as the Chief Executive Officer and President of Generex Biotechnology Corporation, a company that has developed a proprietary alternative (non-invasive; non-injectable) drug delivery system. Ms. Gluskin was a Founder of Generex Biotechnology Corporation and in her role as CEO she was instrumental in raising over $400 million for the company.

Ms. Gluskin has a number of patents for innovative pharmaceutical drugs in her name. She holds a Masters Degree in Microbiology and Genetics from Moscow State University and an equivalent degree from the University of Toronto.

Rose C. Perri, (President) has held management and overseen operations for both private and public companies for the past 20+ years. In 1995, Rose was a co-founder of Generex Biotechnology Corporation, a start-up drug delivery company whose main research and development product was a buccal delivery of insulin.

Rose C. Perri

President

William (Bill) D. Abajian, (Global Business Development & Licensing; M&A) brings over 30 years experience in the pharmaceutical and biotechnology industry. Bill served as the Vice President, Global Business Development at Generex Biotechnology Corporation and held that position until July, 2011. He also held the position of Chief Executive Officer, President and Treasurer and Director of Protect Pharmaceutical Corp. for a short period during 2010.

William (Bill)

Global Business Development